Synthesis, metabolite analysis, and in vivo evaluation of [11C]irinotecan as a novel positron emission tomography (PET) probe

Add time:09/07/2019    Source:sciencedirect.com

IntroductionIrinotecan is a semisynthetic derivative of camptothecin that exerts potent antitumor activity by inhibiting topoisomerase I. Despite much research into the complex pharmacokinetic profile and pharmacodynamic effects of irinotecan, unpredictable and severe side effects are still commonly observed. In this study, we synthesized [11C]irinotecan as a positron emission tomography (PET) probe, performed the metabolite analysis, and evaluated the biodistribution and kinetics of [11C]irinotecan using small animal PET.

We also recommend Trading Suppliers and Manufacturers of Irinotecan hydrochloride trihydrate (cas 136572-09-3). Pls Click Website Link as below: cas 136572-09-3 suppliers

Prev:Interaction of L-myc oncogene in breast cancer with irinotecan onto functionalized magnetic nanoparticles
Next:Rational design of polysorbate 80 stabilized human serum albumin nanoparticles tailored for high drug loading and entrapment of irinotecan)